Cellceutix Pharmaceuticals, Inc. is an emerging bio-pharmaceutical company in the business of developing small molecule therapies in areas of unmet medical need. The Company’s primary efforts are in cancer and inflammatory disease. What differentiates this company from others involved in cancer drug development is their lead product, Kevetrin, which has been shown in cell and animal models to be highly effective in treating drug-resistant cancers. The Company has recently announced some exciting results in animal models of multi-drug resistant lung and breast cancer. Cellceutix is located outside of Boston, Massachusetts. The senior management of Cellceutix is composed of people with long experience in researching, developing and marketing innovative pharmaceutical products.

Website: www.cellceutix.com